Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "LA"

10338 News Found

Cipla appoints Taher Karampurwala as Senior Director and Head of Middle East Business
People | June 03, 2026

Cipla appoints Taher Karampurwala as Senior Director and Head of Middle East Business

Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region


Johnson & Johnson brings India’s first PFA technology for atrial fibrillation treatment
Medical Device | June 03, 2026

Johnson & Johnson brings India’s first PFA technology for atrial fibrillation treatment

New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure


Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350
News | June 03, 2026

Alkem launches single-shot Semaglutide pre-filled syringes at Rs. 350

DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability


Marksans Pharma to acquire Netherlands-based QliniQ
News | June 02, 2026

Marksans Pharma to acquire Netherlands-based QliniQ

Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets


FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG
Drug Approval | June 02, 2026

FDA okays AstraZeneca’s bladder cancer drug Imfinzi Plus BCG

First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death


Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial
Clinical Trials | June 02, 2026

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary


Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
Clinical Trials | June 02, 2026

Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial

The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)


Ebola vax on the anvil?
News | June 02, 2026

Ebola vax on the anvil?

CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate


National Policy Dialogue adopts landmark 10-point declaration for people with disabilities
Healthcare | June 01, 2026

National Policy Dialogue adopts landmark 10-point declaration for people with disabilities

World MS Day 2026 conclave brings together MPs, neurologists, disability rights advocates and insurance stakeholders to push for reforms in healthcare access, disability recognition and social protection


Samsung Bioepis launches Aflibercept biosimilar OPUVIZ across Europe
News | June 01, 2026

Samsung Bioepis launches Aflibercept biosimilar OPUVIZ across Europe

The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments